If the anti-inflammatory effects of tRES-HESP on gene expression in PBMCs translate to tissues, there may be additional health benefits through a decrease of insulin resistance-associated low-grade inflammation in development of non-alcoholic fatty liver disease [49,50,51], chronic kidney disease [52,53], decline of respiratory function [54,55,56], cardiovascular disease, and aging [57,58,59]. The gene discussed is TMPRSS11A; the disease is metabolic dysfunction-associated steatotic liver disease.